Overview

A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Status:
Completed
Trial end date:
2017-09-29
Target enrollment:
Participant gender:
Summary
The objective of this study was to evaluate the efficacy and safety of enzalutamide treatment in patients with progressive metastatic castration-resistant prostate cancer previously treated with abiraterone acetate.
Phase:
Phase 4
Details
Lead Sponsor:
Astellas Pharma Europe B.V.
Collaborator:
Medivation, Inc.